Figure 3
From: Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma
AbTCR + co-stim T cell therapy is safe in humans. (A) Six HCC patients with indicated HLA-A*02 genotypes were dosed as shown over a 17-month period. (B) Lab abnormalities were systematically recorded before the first infusion and immediately after each infusion along with adverse events. Grades are based on the CTCAE scale of 0–5; grade 0 means that physiological measurements were within normal range or that an adverse event was not observed.
